St Cube Inc. (South Korea)

St Cube Inc. is a biopharmaceutical company located in Seoul, South Korea. Founded in 1989, the company is led by biotechnology specialists who aim to make their bio business successful. They have developed innovative new drug candidates that are novel and more effective through their new drug development technology. To secure a competitive edge, St Cube Inc. conducts joint research projects with globally renowned medical research institutions. They also establish close partnerships with multinational pharmaceutical companies for the prompt and efficient development and commercialization of innovative new medicines. The company's main focus is on developing anti-cancer immunotherapeutic agents. They identify immuno-modulatory proteins expressed in various cancer and immune cells and develop antibody and/or small molecule based therapies against them. They aim to find potential immune checkpoint proteins as target candidates for anticancer therapies. St Cube Inc. also develops anti-viral medicines. They focus on immune checkpoint inhibitors that can restore immune functions in patients infected with certain viruses. These inhibitors promote the secretion of immune cells stimulating cytokines, facilitating the removal of infectious viruses. The company's vision is to become a global biopharmaceutical company that focuses on developing innovative new medicines. Their strategies include developing first-in-class therapies for patients with limited response to existing therapies and improving best-in-class therapies for patients who are responsive to existing immunotherapies.